Keyword: biosimilar

Agreement for Biosimilar Candidates in Key Central and Eastern European Markets

• mAbxience and Egis collaborate on the commercialization of two biosimilar candidates • The agreement covers eight Central and Eastern European countries with the potential for expansion into additional territories • mAbxience will serve as the marketing authorization holder, while Egis will manage commercialization in the designated regions

More

Egis Strengthens European Presence in the Biosimilar Area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

More

Gran Prize - Egis Innovation for Sustainability

Egis has developed a new procedure for the dehalogenation of technological wastewaters. In 2018, the Swedish Chamber of Commerce in Hungary recognized the innovation with the Gran Prize Interdisciplinary Innovative award.

More

Active Agent Production Renewed

By renewing our active agent base, we wish to simultaneously raise the rate of our active agents produced internally in a reliable quality and at a competitive price as well as to increase our exports.

More
Channels
Egis World
Egis´ products are sold to more than 100 countries.
Our People
Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life
Health
The company’s product portfolio consisted of more than 650 products
Innovation
In the 2022/2023 business year, we spent EUR 48 million on research and development
Corporate Social Responsibility
Healthcare and sharing knowledge are in the heart of our CSR activities
Events
Our highlighted past and future events you shouldn't miss

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
Egis’ website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.
Only accept necessary cookies
I agree
Details
Cookie Settings
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox
Lightbox Image
✖